Status: Recruiting
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutations.
Participants needed: 345
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Pierre Fabre MedicamentUpdated: Sep 2, 2026Locations: 25
Eligibility criteria
Has histologically- or cytologically confirmed diagnosis of NSCLC Stage IIIB/C o... [+7]
Has a tumor that is known to harbor EGFR ex20ins p.H773_V774insH variant, or any... [+4]